Voices

Hung Trinh: BioNTech SE and Bristol Myers Squibb Partner on Next-Gen Bispecific Antibody for Solid Tumors

Hung Trinh/LinkedIn

Aug 11, 2025, 17:31

Hung Trinh: BioNTech SE and Bristol Myers Squibb Partner on Next-Gen Bispecific Antibody for Solid Tumors

Hung Trinh, Senior VP of Operations at Seneca Therapeutics, shared a post on LinkedIn:

“BioNTech SE and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types

BNT327, BioNTech’s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set a new standard of care in multiple tumor types

The co-development and co-commercialization collaboration with a 50/50 profit/loss split will leverage both partners’ expertise, resources and global footprint to accelerate BNT327’s path towards potential regulatory approvals and market launches
BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types

MAINZ, Germany & PRINCETON, N.J.–(BUSINESS WIRE)– BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb (NYSE: BMY, “BMS”) today announced that the companies have entered into an agreement for the global co-development and co-commercialization of BioNTech’s investigational bispecific antibody BNT327 across numerous solid tumor types. Under the agreement, BioNTech and BMS will work jointly to broaden and accelerate the development of this clinical candidate.

BioNTech’s BNT327, a next-generation bispecific antibody candidate targeting PD-L1 and VEGF-A, is currently being evaluated in multiple ongoing trials with more than 1,000 patients treated to date, including global Phase 3 trials with registrational potential evaluating BNT327 as first-line treatment in extensive stage small cell lung cancer (“ES-SCLC”) and non-small cell lung cancer (“NSCLC”).

A global Phase 3 trial evaluating the candidate in triple negative breast cancer (“TNBC”) is planned to start by the end of 2025. Preliminary data from ongoing trials underscore the potential for combining anti-PD-L1 and anti-VEGF-A – two well-established therapeutic targets – into a single molecule to deliver synergistic clinical benefits for patients across multiple tumor types.

Read further.”

More posts featuring Hung Trinh.